Drug Information Related to Pantoprazole Sodium
Back
01. Teva Announces Approval of Generic Protonix(R) Delayed Release Tablets...
JERUSALEM -- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA)
announced today that the U.S. Food and Drug Administration has granted
final approval for the Company's Abbreviated New Drug Application
(ANDA) to market its generic version of Wyeth's Protonix[R]
(...
02. Teva Receives Tentative Approval for Generic Protonix(R) Delayed ......
JERUSALEM -- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Wyeth's Protonix Pro·...
03. Teva Provides Update on Generic Protonix(R). - Free Online Library...
JERUSALEM, Israel -- Teva Pharmaceutical Industries Ltd.
(Nasdaq:TEVA) announced today following their press release dated
January 29, 2008, that the Company has not relaunched and does not
intend to ship additional units of generic Protonix[R] (Pantoprazole
Sod...
04. Teva Announces Extension to Standstill Agreement on Generic Protonix(R...
JERUSALEM -- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA)
announced today that further to its press release dated December 24,
2007, the Company and Wyeth/Altana have agreed to extend their
standstill agreement regarding generic Protonix[R] (Pantoprazole
S...
05. Adnexus Therapeutics Announces Appointment of Timothy J. Rink, MD, ScD...
WALTHAM, Mass. -- Adnexus Therapeutics, Inc. today announced
Timothy J. Rink, MD, ScD has joined the Adnexus Board of Directors. Dr.
Rink also currently serves as chairman of the Strategy Panel of the
Technology Transfer division of the Wellcome Trust that funds ...
06. DDMAC UNTITLED LETTERS. - Free Online Library
The following untitled letters were issued by the Centers for
Drugs' Division of Drug Marketing, Advertising and Communications
(DDMAC). Copies of these letters are available to subscribers from our
RECORD-RETRIEVE service for $7 plus retrieval. Please referen...
07. PANTOPRAZOLE SODIUM.(Protonix IV anticancer drug from American Home .....
PANTOPRAZOLE SODIUM American Home Products Corp. has received FDA approval for Protonix I.V (pantoprazole sodium) for injection to treat pathological hypersecretory conditions ...
...
08. Teva Receives Tentative Approval for Generic Protonix® Delayed Releas...
JERUSALEM -- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Wyeth's Protonix(R) (Pa...
09. New proton pump inhibitor approved | Nurse Practitioner | Find Article...
The FDA has approved American Home Products' pantoprazole sodium (Protonix) delayed-release tablets for short-term treatment in the healing and symptomatic relief of erosive esophagitis.
...
10. Positive Clinical Data with Santarus' ZEGERID Capsules in Controlling ...
Morning Dosing of ZEGERID Produced Rapid and Sustained Control of Gastric Acidity in Patients
...
11. Teva Announces Extension to Standstill Agreement on Generic Protonix ....
JERUSALEM -- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that further to its press release dated December 24, 2007, the Company and Wyeth/Altana have agreed to extend their standstill agreement regarding generic Protonix[R] (Pantoprazole Sodium)...
12. FDA OKs IV treatment for acid reflux | Healthcare Purchasing News ......
...
13. Teva Announces Wyeth Voids Standstill Agreement on Generic Protonix .....
JERUSALEM -- Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced today that the Company's standstill agreement with Wyeth/Altana regarding additional shipments by Teva of generic Protonix (Pantoprazole Sodium) has terminated as a result of Wyeth's launch of an...
14. First I.V. proton pump inhibitor approved | Nursing | Find Articles at...
PROTONIX
...
15. Pharmaceutical foreground is riddled with generic competition, OTC ......
Pharmaceutical manufacturers have a rough road ahead this year, pockmarked by generic competition and managed care issues. In fact, Doug Long, IMS Health vice president of industry relations, named generic erosion and the potential impact three-tiered co-pay systems w...